PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
Adverse Reactions/Side Effects Generalized: Anaphylactic shock and death have been reported with administration of parenteral vitamin B 12 (see WARNINGS)
Most compounded tirzepatide remains stable for 30 days when maintained at proper refrigeration, though your pharmacy will provide specific expiration guidance based on their formulation protocol
Risks vary by peptide, dose, and individual health context
Allergic Reactions: In rare cases, individuals may experience allergic reactions to MIC+B12 injections, which can manifest as hives, itching, rash, difficulty breathing, or swelling of the face, lips, tongue, or throat
In weight-management settings, clinics often recommend weekly or biweekly MIC/B12 shots in 412 week programs